Fundraising Overview - The company raised a total of RMB 6,447,000,000.00 from the issuance of 30 million shares at a price of RMB 21.49 per share, with a net amount of RMB 6,067,191,792.45 after deducting issuance costs [1] - As of June 30, 2025, the company has utilized RMB 5,988,460,123.88 of the raised funds, including RMB 1,782,167,500.00 for replacing self-raised funds and RMB 492,850,221.22 for supplementing working capital [1] Fund Management - The company has established dedicated accounts for the management of raised funds, complying with relevant regulations [1] - A tripartite supervision agreement was signed with various banks to ensure proper management of the funds [1] - The initial amount deposited in the dedicated accounts was RMB 6,104,068,000.00, with differences attributed to prepaid underwriting and other issuance costs [1] Fund Usage - During the reporting period, the company did not use raised funds to replace self-raised funds or temporarily supplement working capital [2] - There were no instances of using idle raised funds for cash management or to repay bank loans [2] - The company has completed the transfer of surplus raised funds to working capital and closed the relevant dedicated accounts [1][2] Project Investment Status - The company has completed the investment projects as planned, with the "Annual Production of 35,000 Tons of Polysilicon Project" and "Annual Production of 1,000 Tons of High-Purity Semiconductor Materials Project" reaching their intended operational status [3] - The polysilicon project generated an annual revenue of RMB 51,325.32 million, which was below the expected revenue due to market factors [3] - The high-purity semiconductor materials project is currently in the verification stage and has not yet achieved the expected benefits [4]

Fundraising Overview - The total amount raised through the non-public offering was RMB 448,378 million, with a net amount of RMB 445,619.87 million after deducting issuance costs [1] - As of June 30, 2025, RMB 12,166.07 million of the raised funds had been utilized, leaving a balance of RMB 9,477.74 million [2][4] - The remaining balance includes RMB 7,605.99 million temporarily used to supplement working capital, while RMB 2,307.66 million is in the special account [2][4] Fund Management - The company has established a fundraising management system to regulate the storage, use, and supervision of the raised funds [2] - Special accounts for the raised funds have been opened with commercial banks, and a tripartite supervision agreement has been signed with the sponsor and banks [3] Fund Utilization - The actual use of the raised funds during the reporting period was RMB 12,166.07 million, with no instances of replacing the funds [4][8] - As of June 30, 2025, RMB 7,605.99 million of the temporarily supplemented working capital had been returned by July 7, 2025 [5][9] Changes in Fund Investment Projects - The company approved adjustments to the investment amounts for certain projects to enhance the efficiency of fund usage, including reallocating RMB 19,314 million to a new project related to innovative drug clinical trials [6][10] - New sub-projects have been added, with specific reallocations including reductions for "Balixafortide" and "COVID-19 mRNA vaccine" projects, and increases for "FS-1502," "FCN-338," and "SAF-189" projects [6][9] Compliance and Disclosure - The company has complied with relevant regulations regarding the use and disclosure of raised funds, ensuring timely and accurate reporting [6][7]

Core Viewpoint - The report details the fundraising activities and the usage of raised funds by Tianjin Bohai Chemical Co., Ltd. for the period ending June 30, 2025, highlighting the management, allocation, and changes in investment projects. Fundraising Overview - The company raised a total of RMB 706.02 million through a non-public offering of 183,381,314 shares at RMB 3.85 per share, with the funds verified by an independent auditor [1][2]. - The funds are managed under specific regulations and stored in dedicated accounts to ensure proper usage and efficiency [1][2]. Fund Management - The company has established a fundraising management method to ensure that the funds are used efficiently and in compliance with relevant regulations [1][2]. - A four-party supervision agreement was signed with independent financial advisors and banks to oversee the management of the raised funds [1][2]. Fund Usage - As of June 30, 2025, the total amount of funds used was RMB 281.55 million, with RMB 200 million temporarily allocated to supplement working capital and RMB 281.55 million invested in projects [1][2][3]. - The remaining balance of the raised funds was RMB 256.78 million after accounting for the temporary working capital allocation [1][2][3]. Project Changes - The company changed the investment focus from the "Propane Dehydrogenation Unit Technology Transformation Project" to the "Acrylic Ester and Superabsorbent Resin New Material Project" due to market conditions affecting the original project [2][6]. - The new project is located in the Tianjin Port Free Trade Zone and is currently being implemented as planned [2][6]. Idle Fund Management - The company has not engaged in cash management activities for idle funds during the reporting period [3]. - A resolution was passed to use up to RMB 350 million of idle funds for cash management, with a rolling usage period of up to 12 months [2][3]. Investment Project Status - The company has not transferred or replaced any investment projects with the raised funds, and the projects are being executed according to the planned schedule [1][2][3]. - The company has confirmed that the actual usage of funds aligns with the disclosures in periodic reports, with no significant discrepancies noted [1][2].

Core Viewpoint - The report provides an audit of Tianjin Bohai Chemical Co., Ltd.'s fundraising activities and the actual use of raised funds for the first half of 2025, confirming compliance with regulations and accurate reporting of fund usage [1][2]. Fundraising Overview - The company raised a total of RMB 706,018,058.90 through a non-public offering of 183,381,314 shares at RMB 3.85 per share, with net proceeds amounting to RMB 69,895.79 million after deducting issuance costs [2][3]. - The funds are managed under a specific management plan to ensure proper usage and efficiency, with dedicated accounts for storage [2][3]. Fund Storage and Usage - As of June 30, 2025, the total balance of the raised funds was RMB 25,677.51 million after accounting for various expenditures, including RMB 20,000 million temporarily used for working capital and RMB 28,154.60 million invested in projects [2][3]. - The company has established a four-party supervision agreement for the management of the raised funds, ensuring compliance with regulatory requirements [2][3]. Project Investment and Changes - The company has changed the investment focus from the "Propane Dehydrogenation Unit Technical Transformation Project" to the "Acrylic Ester and Super Absorbent Resin New Material Project" due to market conditions affecting the feasibility of the original project [2][3][5]. - The new project is currently being implemented as planned, with no significant changes in feasibility reported [5][6]. Idle Fund Management - The company has not engaged in cash management activities for idle funds during the reporting period, and no permanent use of excess funds for working capital or loan repayment has occurred [4][6]. - A temporary use of up to RMB 20,000 million of idle funds for working capital was approved, with a commitment to return the funds to the dedicated account as needed [4][6].

证券代码：688577 证券简称：浙海德曼 公告编号：2025-023 浙江海德曼智能装备股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 (二) 募集资金专户存储情况 经中国证券监督管理委员会《关于同意浙江海德曼智能装备股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1644号）同意注册，本公司由 主承销商民生证券股份有限公司采用向战略投资者定向配售、网下向符合条件的 投资者询价配售和网上向持有上海市场非限售A股股份和非限售存托凭证市值的 社会公众投资者定价发行相结合的方式发行人民币普通股（A股）股票1,350.00万 股，发行价为每股人民币33.13元，共计募集资金44,725.50万元，坐扣承销和保 荐费用（不含税）3,800.00万元后的募集资金为40,925.50万元，已由主承销商民 生证券股份有限公司于2020年9月10日汇入本公司募集资金监管账户。另除律师费、 审计费、法定信息披露等其他发行费用2,730.87万元后，公 ...

浙江海德曼智能装备股份有限公司 募集资金管理制度 浙江海德曼智能装备股份有限公司 募集资金管理制度 浙江海德曼智能装备股份有限公司 募集资金管理制度 第一章 总则 公司应当将募集资金存储、使用和管理的内部控制制度及时在上海证券交易 所网站上披露。 第五条、公司董事、高级管理人员应当勤勉尽责，督促公司规范运用募集资 金，自觉维护公司募集资金安全，不得参与、协助或纵容公司擅自或变相改变募 集资金用途。 浙江海德曼智能装备股份有限公司 募集资金管理制度 第一条、为规范浙江海德曼智能装备股份有限公司（以下简称"公司"）募 集资金的管理，提高募集资金使用的效率和效果，确保资金使用安全，维护投资 者合法利益，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交 易所科创板股票上市规则》（以下简称《股票上市规则》）、《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》等有关法律、法规和规范性文件 的规定，结合公司的实际情况，制定本制度。 第二条、本制度所称募集资金系指公司通过公开发行股票及其衍生品种，向 投资者募集并用于特定 ...

Group 1 - The board of directors of Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. held its fourth meeting of the sixth session on August 15, 2025, with all nine directors present, ensuring compliance with relevant laws and regulations [1] - The board approved the annual report and its summary, with detailed content available on the company's disclosure platform [1][2] - The board also approved a special report on the use of raised funds, which was reviewed by the audit committee [2][3] Group 2 - The board authorized the core management team to handle changes related to the raised funds account, including the cancellation and opening of accounts [3] - A temporary shareholders' meeting is scheduled for September 15, 2025, to discuss various proposals, including changes to the company's registered capital and amendments to the articles of association [2][3] - The company aims to improve the efficiency of fund usage by transferring the balance of raised funds to a different bank account [2][3]

Core Points - The article outlines the fundraising management system of Shanghai MicroPort CardioMed Technology (Group) Co., Ltd, aiming to enhance the safety and efficiency of fund usage while protecting investors' rights [2][21] - The system is established in accordance with various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [2] Fundraising Management - The company defines fundraising as funds raised through the issuance of securities to unspecified or specific objects, excluding funds raised for equity incentive plans [2] - Upon receipt of funds, the company must promptly conduct verification procedures and ensure that funds are stored in a designated account approved by the board of directors [4][6] - The board of directors is responsible for the management and usage of the raised funds, with oversight from the audit committee and sponsor institutions [2][3] Fund Storage - Funds must be stored in a special account dedicated to fundraising, and cannot be used for other purposes [4][6] - A tripartite supervision agreement must be signed with the sponsor institution and the commercial bank within one month of the funds being received [6] Fund Usage - The company must use the raised funds in accordance with the approved investment plans and must disclose any significant deviations from these plans [9][10] - If a project cannot be completed within the original timeframe, the company must disclose the reasons and the current status of the funds [10][11] - The company is prohibited from using the funds for financial investments or providing them to controlling shareholders for improper benefits [12][13] Changes in Fund Usage - Any changes in the use of raised funds must be approved by the board of directors and disclosed to shareholders [20][21] - The company must conduct feasibility analyses for new investment projects and ensure that they align with the main business operations [22][23] Oversight and Reporting - The company is required to regularly disclose the status of fund usage and any changes in investment plans in its annual and semi-annual reports [16][20] - The sponsor institution or independent financial advisor must conduct ongoing supervision and report any irregularities to the Shanghai Stock Exchange [16][17]

Core Points - The board of directors of Xinyin Electronics held its second meeting on August 26, 2025, to review and approve several key proposals [1][2][3] Meeting Details - The meeting was conducted both in-person and via communication, with all eight directors present, ensuring compliance with relevant laws and regulations [1] - The board confirmed the authenticity and completeness of the 2025 semi-annual report [2] Profit Distribution - The board approved a profit distribution plan, proposing a cash dividend of 1.15 yuan per 10 shares (including tax) to all shareholders, with no stock distribution or capital reserve conversion [2] Fund Management - The board affirmed that the information regarding the management and use of raised funds for the first half of 2025 was accurate and complete, with no violations reported [3] Management Changes - The board appointed Zeng Cibin as the deputy general manager and Gu Li as the financial manager, following the resignation of Zeng Cibin from the financial manager position [3] Audit Firm Appointment - The board agreed to continue the appointment of Rongcheng Accounting Firm for the 2025 financial and internal control audits, with prior approval from the audit committee [4] Asset Sale - The board approved the sale of industrial land use rights in Jiangsu Province to enhance asset efficiency and liquidity, with the transaction price based on the asset's book value [4] Articles of Association Revision - The board agreed to revise the company's Articles of Association and authorized the board to handle subsequent filing matters, pending approval from regulatory authorities [5] Upcoming Shareholder Meeting - A second extraordinary general meeting of shareholders is scheduled for September 11, 2025, to review the proposals requiring shareholder approval [6][7]

本次会议由监事会主席梁展毅先生主持，公司董事会秘书兼财务总监江柯列 席本次会议。经与会监事认真审议，形成了如下决议： 二、监事会会议审议情况 （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 证券代码：001229 证券简称：魅视科技 公告编号：2025-021 广东魅视科技股份有限公司 第二届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 广东魅视科技股份有限公司（以下简称"公司"）第二届监事会第八次会议 于 2025 年 8 月 26 日在公司会议室以现场结合远程视频方式召开，会议通知以电 子邮件方式已于 2025 年 8 月 15 日向各位监事发出，本次会议应参加监事 3 名， 实际参加监事 3 名（其中，现场参加的监事为梁展毅和陈龙光，以远程视频方式 参会的监事为叶木波），本次会议的召开符合《中华人民共和国公司法》等有关 法律、法规及《公司章程》的规定。 监事会认为：2025 年上半年，公司严格按照《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》和公司《募集资金 ...